Nevropatiya i prediabet: eti chasy nachinayut tikat' rano
- Authors: Ametov A.S1, Lysenko M.A1
-
Affiliations:
- Issue: No 16 (2012)
- Pages: 11-15
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279920
- ID: 279920
Cite item
Open Access
Access granted
Abstract
The article discusses the problem of diabetic neuropathy as one of the most common complications of diabetes mellitus (DM). According to a number of clinical studies, the prevalence of diabetic peripheral neuropathy is 30-50 % of all DM patients, and idiopathic neuropathy, according to some authors, is a marker of pre-diabetes. The role of timely diagnosis and early initiation of therapy for the successful treatment of diabetic neuropathy and prevention of development of serious DM complications is emphasized.
Keywords
Full Text
References
- Young M.J., Boulton A.J.M., Macleod A.F, et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993;36:150-54.
- Аметов А.С. Сахарный диабет. Проблемы и решения. Руководство. М., 2011. 680 с.
- King R.H. The role of glycation in the pathogenesis of diabetic polyneuropathy. Mol Pathol 2001;54:400-08.
- Ziegler D., Sohr C.G.H., Nourooz-Zadeh J. Oxidative Stress and Antioxidant Defense in Relation to the Severity of Diabetic Polyneuropathy and Cardiovascular Autonomic Neuropathy. Diabetes Care 2004;27:2178-83.
- Доказательная эндокринология / Перевод с англ. 2-е изд. М., 2008. С. 415-16.
- Greene D.A., Stevens M.J., Feldman E.L. The sorbitol-osmotic and sorbitol-redox hypothesis. In: LeRoith D., Taylor S., Olefsky J.M., ed. Diabetes mellitus: a fundamental and clinical text. Philadelphia' Lipincott Williams & Wilkins, 1996.
- Burchiel K.J., Russell L.C., Lee R.P., Sima A.A.F. Spontaneous activity of primary afferent neurons in diabetic BB/wistar rats: a possible mechanism of chronic diabetic neuropathic pain. Diabetes 1985;36:1210-13.
- Boulton A. What causes neuropathic pain? J Diabetes its Complicat 1992;6:58-63.
- Ziegler D., Rathmann W., Dickhaus T., et al. For the Kora Study Group. Diabetes Care 2008;31: 464-69.
- Franklin G.M., Kahn L.B., Baxter J., et al. Sensory neuropathy in non-insulin-dependent diabetes mellitus:the San Luis Valley Diabetes Study. Am J Epidemiol 1990;131:633-43.
- Papanas N., Vinik A.I., Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? Nat Rev Endocrinol 2011;7(11):682-90.
- Ефимов А.С. Диабетические ангиопатии. М., 1989.
- Brownly M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
- Моргоева Ф.Э., Аметов А.С., Строков И.А. Диабетическая энцефалопатия и поли невропатия: терапевтические возможности Актовегина // РМЖ 2005. № 6. С. 302-04.
- Яворская В.А., Егоркина О.В., Машкин О.Н. и др. Клинический опыт применения Актовегина при диабетической полинейропатии / В сб. "Опыт клинического применения актовегина в эндокринологии". М., 2005. С. 27-30.
- Jansen W., Beck E. Лечение диабетической полинейропатии. Контролируемое двойное слепое исследование / В сб. "Опыт клинического применения актовегина в эндокринологии". М., 2005. С. 11-20.
- Строков И.А. Результаты плацебоконтролируемого многоцентрового исследования "Актовегин по сравнению с плацебо у пациентов с диабетической полиневропатией" // Атмосфера. Нервные болезни 2009. № 4. С. 17-21.
- Ziegler D., Movsesyan L., Mankovsky B., et al. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care 2009;32(8):1479-84.
Supplementary files
